scholarly journals PCV44 COST-EFFECTIVENESS OF PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION: ANALYSIS OF REAL WORLD DATA

2019 ◽  
Vol 22 ◽  
pp. S126-S127
Author(s):  
T.H. Hsieh ◽  
C.Y. Shih ◽  
P.Y. Liu ◽  
J.S. Hwang ◽  
J.D. Wang
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Percutaneous Coronary Intervention ◽  
Cost Effectiveness ◽  
Real World ◽  
Coronary Intervention ◽  
Real World Data ◽  
World Data ◽  
Percutaneous Coronary

RETROSPECTIVE STUDY OF CLINICAL & EPIDEMIOLOGICAL PARAMETERS OF PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WITH THEIR FOLLOW-UP

2021 ◽  
pp. 38-40
Author(s):  
Sunil Washimkar ◽  
Rohan Parikh ◽  
Atul Singh Rajput ◽  
Pradeep Deshmukh
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Stent Thrombosis ◽  
Real World ◽  
Second Generation ◽  
Coronary Intervention ◽  
Real World Data ◽  
World Data ◽  
Percutaneous Coronary ◽  
Epidemiological Parameters

Aim:To study clinical and epidemiological parameters of patients undergoing percutaneous coronary intervention (PCI) and to follow them up for understanding outcomes of procedure. Materials & methods:This is retrospective data analysis of 862 patients who underwent PCI from January 2016 to November 2017 Results: Out of 862 patients, 611 (70.88%) were male & 251 (29.12%) were female, with mean age being 55. 243 (28.19%) were diabetic, 470 (54.52%) were hypertensive, 158 (18.32%) patients were tobacco chewer, 215 (24.92%) were smokers & 111 (12.87%) were alcoholic. 636 (73.78%) patients had STEMI, 153 (17.74%) had NSTE-ACS, 61 (7.07%) had CSA.578 (67.05%) were SVD, 262 (30.39%) were DVD & 19 (2.20%) were TVD. Out of SVD, 350 (60.55%) patients had LAD involvement and among DVD patients, LAD & RCA were most commonly involved in 107 (40.83%) patients. On follow-up of mean 604.42 days (minimum 236 days, maximum 909 days), 2 (0.23%) episodes of subacute stent thrombosis occurred & 11 (1.27%) patients had ISR but no mortality was reported. Summary: The study shows affection of young population predominately and gender inequality suggesting primarily male disease. PCI is often sought in ACS and CSAis predominately treated medically. Thrombolysis still remains the rst treatment received by STEMI patients. SVD is the most common angiographic diagnosis with LAD predominately affected vessel. This real world-data on clopidogrel with aspirin as dual antiplatelet therapy and second generation stent shows negligible event of stent thrombosis & ISR. Limitation: Due to non-invasive follow-up, exact amount of stent restenosis can not be calculated. Impact on daily practice: This real world-data on clopidogrel with aspirin as dual anti-platelet therapy and second generation stent shows negligible event of stent thrombosis & ISR. This can help reduce cost burden on society and help better distribution of health budget.

scholarly journals Cost-effectiveness of percutaneous coronary intervention versus medical therapy in patients with acute myocardial infarction: real-world and lifetime-horizon data from Taiwan

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Chia-Te Liao ◽  
Tung-Han Hsieh ◽  
Chia-Yin Shih ◽  
Ping-Yen Liu ◽  
Jung-Der Wang
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Percutaneous Coronary Intervention ◽  
Cost Effectiveness ◽  
Survival Function ◽  
Coronary Intervention ◽  
Medical Costs ◽  
Life Years ◽  
Percutaneous Coronary ◽  
The Cost

AbstractAlthough some studies have assessed the cost-effectiveness of percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI), there has been a lack of nationwide real-world studies estimating life expectancy (LE), loss-of-LE, life-years saved, and lifetime medical costs. We evaluated the cost-effectiveness of PCI versus non-PCI therapy by integrating a survival function and mean-cost function over a lifelong horizon to obtain the estimations for AMI patients without major comorbidities. We constructed a longitudinal AMI cohort based on the claim database of Taiwan's National Health Insurance during 1999–2015. Taiwan's National Mortality Registry Database was linked to derive a survival function to estimate LE, loss-of-LE, life-years saved, and lifetime medical costs in both therapies. This study enrolled a total of 38,441 AMI patients; AMI patients receiving PCI showed a fewer loss-of-LE (3.6 versus 5.2 years), and more lifetime medical costs (US$ 49,112 versus US$ 43,532). The incremental cost-effectiveness ratio (ICER) was US$ 3488 per life-year saved. After stratification by age, the AMI patients aged 50–59 years receiving PCI was shown to be cost-saving. From the perspective of Taiwan's National Health Insurance, PCI is cost-effective in AMI patients without major comorbidities. Notably, for patients aged 50–59 years, PCI is cost-saving.

2-year real-world outcomes of prasugrel, ticagrelor or clopidogrel therapy following percutaneous coronary intervention from a large multi-centre Australian registry

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
D Pol ◽  
E Chowdhury ◽  
S Delacroix ◽  
S Worthley ◽  
D Eccleston
Keyword(s):  
Myocardial Infarction ◽  
Percutaneous Coronary Intervention ◽  
Major Bleeding ◽  
Real World ◽  
Coronary Intervention ◽  
Real World Data ◽  
End Point ◽  
Percutaneous Coronary ◽  
Clopidogrel Therapy ◽  
Coronary Syndromes

Abstract Background Real-world data comparing outcomes for prasugrel, ticagrelor or clopidogrel use in patients undergoing percutaneous coronary intervention (PCI) is limited, with only smaller cohorts or 12-month observations available. Methods Data was collected prospectively from a total of 14 sites around Australia, from November 2008 until March 2019. The cohort included consecutively enrolled patients presenting electively or following acute coronary syndromes who were prescribed dual antiplatelet therapy following PCI. There were no exclusion criteria. The primary end point was the composite of death, myocardial infarction, or stroke at 1 year and 2 years after PCI. Secondary end points included safety, which was the incidence of major bleeding (BARC 3,4 or 5) at discharge. Results A total of 12,940 patients were included over a 11-year period. Patients receiving prasugrel were more likely to be male, younger (mean age 62.3+8.7 years), obese and present with STEMI than those receiving either ticagrelor or clopidogrel (all p<0.001). At 2 years the primary end point occurred in 120 of the 2968 patients (2.8 per 1000pyr) in the ticagrelor group, 446 of 9280 (2.7 per 1000pyr) patients in the clopidogrel group and 21 of 692 (1.8 per 1000pyr) prasugrel group (p=0.03). Major bleeding was observed in 0.2% in the ticagrelor group, 0.4% clopidogrel group and 0.1% in the prasugrel group (p=0.21). Conclusion For the first time we have shown in a large cohort of patients treated by PCI for ACS or CAD significantly lower 2-year rates of death, myocardial infarction and stroke amongst patients who received prasugrel than among those who received either clopidogrel or ticagrelor. The incidence of major bleeding did not differ between antiplatelet therapies. Funding Acknowledgement Type of funding source: None

Sign in / Sign up

Export Citation Format

Share Document